ApprovedFDA approval

Juvmo (tavapadon)

AbbVie (ABBV)

Marketer take

A new Parkinson's option in a crowded, largely generic market built on levodopa and dopamine agonists, so movement-disorder specialists and neurologists will need clear positioning on where it fits in therapy.

Sponsor company
AbbVie (ABBV)
Indication
To treat Parkinson’s disease in adults
Therapeutic area
Neurology
Event
FDA approval
Date
Sep 25, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move